A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance

被引:34
作者
Whiteside, MA
Chen, DT
Desmond, RA
Abdulkadir, SA
Johanning, GL
机构
[1] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA
[2] NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA
[3] Univ Alabama Birmingham, Biostat & Bioinformat Unit, Birmingham, AL USA
[4] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
关键词
lung cancer; drug resistance; gene expression profiling; mechanisms of drug action;
D O I
10.1038/sj.onc.1207164
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent years, most cDNA microarray studies of chemotherapeutic drug resistance have not considered the temporal pattern of gene expression. The objective of this study was to examine systematically changes in gene expression of NCI-H226 and NCI-H2170 lung cancer cells treated weekly with IC10 doses of cisplatin. NCI-H226 lung cancer cells were treated weekly with an IC10 dose of cisplatin. Candidate genes with a fold change of 2.0 or more were identified from this study. A second experiment was conducted by exposing NCI-H2170 cells to cisplatin doses that were increased in week 4 and decreased in week 5. Overall, 44 genes were differentially expressed in both the NCI-H226 and NCI-H2170 cell lines. In the NCI-H2170 cell line, 24 genes had a twofold gene expression change from weeks 3 to 4. Real-time PCR found a significant correlation of the gene expression changes for seven genes of interest. This small time-ordered series identified novel genes associated with cisplatin resistance. This kind of analysis should be viewed as a first step towards building gene-regulatory networks.
引用
收藏
页码:744 / 752
页数:9
相关论文
共 34 条
[1]   BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair [J].
Abbott, DW ;
Thompson, ME ;
Robinson-Benion, C ;
Tomlinson, G ;
Jensen, RA ;
Holt, JT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18808-18812
[2]  
Amundson SA, 2000, CANCER RES, V60, P6101
[3]  
ANDERSON IC, 1995, CANCER RES, V55, P4120
[4]  
Anderson KM, 2002, ANTICANCER RES, V22, P75
[5]   The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].
Bhattacharyya, A ;
Ear, US ;
Koller, BH ;
Weichselbaum, RR ;
Bishop, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903
[6]  
Bolon I, 1997, AM J PATHOL, V150, P1619
[7]   MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily [J].
Bootcov, MR ;
Bauskin, AR ;
Valenzuela, SM ;
Moore, AG ;
Bansal, M ;
He, XY ;
Zhang, HP ;
Donnellan, M ;
Mahler, S ;
Pryor, K ;
Walsh, BJ ;
Nicholson, RC ;
Fairlie, WD ;
Por, SB ;
Robbins, JM ;
Breit, SN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) :11514-11519
[8]  
Boulay A, 2001, CANCER RES, V61, P2189
[9]  
Brognard J, 2001, CANCER RES, V61, P3986
[10]   Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance [J].
Campbell, RA ;
Bhat-Nakshatri, P ;
Patel, NM ;
Constantinidou, D ;
Ali, S ;
Nakshatri, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9817-9824